|
市場調査レポート
商品コード
1441233
肺炎治療の世界市場規模、シェア、成長分析、治療法別、流通チャネル別-産業予測、2023～2030年Global Pneumonia Therapeutics Market Size, Share, Growth Analysis, By Treatment(Antibiotics, antiviral drugs), By Distribution channel(Hospital pharmacies, retail pharmacies) - Industry Forecast 2023-2030 |
||||||
|
|
|||||||
| 肺炎治療の世界市場規模、シェア、成長分析、治療法別、流通チャネル別-産業予測、2023～2030年 |
|
出版日: 2024年02月22日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
肺炎治療の世界市場規模は2022年に95億米ドルと評価され、予測期間中（2024～2031年）のCAGRは9.0%で、2023年の103億6,000万米ドルから2031年には206億3,000万米ドルに成長する展望です。
世界の肺炎治療市場は、特に高齢者や免疫不全者における肺炎の有病率の増加、革新的な治療法の継続的な開発など、さまざまな要因によって推進されています。医療施設外で発症する市中肺炎（CAP）は依然として重要な懸念事項であり、早期診断と適切な治療に関する意識の高まりにつながっています。このような意識は、診断技術の向上、より正確な評価ツールの開発、治療成果を最適化するための医療従事者向けガイドラインの確立に拍車をかけています。この市場には、様々な抗生物質、抗ウイルス薬、支持療法が含まれます。医療技術の進歩が進み、個別化医療が重視されるようになったことで、研究開発の努力はより的を絞った効率的な治療に向けられています。しかし、地域によっては抗生物質耐性や医療アクセスの制限といった課題も残っています。全体として、肺炎治療市場は、現在進行中の医療の進歩と人口動態の動向により成長する位置にあります。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
肺炎治療の世界市場：治療別
- 市場概要
- 抗生物質
- 抗ウイルス薬
- 支持療法
肺炎治療の世界市場：流通チャネル別
- 市場概要
- 病院薬局
- 小売薬局
- とオンラインプラットフォーム
肺炎治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Pfizer Inc.-米国
- GlaxoSmithKline plc（GSK）-英国
- AstraZeneca plc-英国
- Novartis AG-スイス
- Roche Holding AG-スイス
- Merck & Co., Inc.-米国
- Sanofi-フランス
- Johnson & Johnson-米国
- Eli Lilly and Company-米国
- Bayer AG-ドイツ
- Boehringer Ingelheim-ドイツ
- AbbVie Inc.-米国
- Bristol Myers Squibb-米国
- Teva Pharmaceutical Industries Ltd.-イスラエル
- Mylan N.V.-米国
- Allergan（AbbVieの一部）-米国
- Vertex Pharmaceuticals-米国
- Astellas Pharma Inc.-日本
- Daiichi Sankyo Co., Ltd.-日本
- Takeda Pharmaceutical Company Limited-日本
Global Pneumonia Therapeutics Market size was valued at USD 9.50 Billion in 2022 and is poised to grow from USD 10.36 Billion in 2023 to USD 20.63 Billion by 2031, at a CAGR of 9.0% during the forecast period (2024-2031).
The global pneumonia therapeutics market is propelled by various factors, including the increasing prevalence of pneumonia, particularly among the elderly and immunocompromised individuals, and the continuous development of innovative treatment options. Community-acquired pneumonia (CAP), acquired outside of healthcare facilities, remains a significant concern, leading to heightened awareness regarding early diagnosis and appropriate treatment. This awareness has spurred improvements in diagnostic techniques, more accurate assessment tools, and the establishment of guidelines for healthcare practitioners to optimize treatment outcomes. The market encompasses a variety of antibiotics, antiviral drugs, and supportive care therapies. With ongoing advancements in medical technology and a growing emphasis on personalized medicine, research and development efforts are directed towards more targeted and efficient treatments. However, challenges such as antibiotic resistance and limited healthcare access in certain regions persist. Overall, the pneumonia therapeutics market is positioned for growth due to ongoing medical advancements and demographic trends.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumonia Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.
Global Pneumonia Therapeutics Market Segmental Analysis
The global pneumonia therapeutics market can be segmented based on treatment, distribution channel, and region. Treatment types include antibiotics, antiviral drugs, and supportive care. Distribution channels involve hospital pharmacies, retail pharmacies, and online platforms. Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Drivers of the Global Pneumonia Therapeutics Market
Pneumonia represents a substantial global health concern, particularly affecting vulnerable populations such as the elderly, young children, and individuals with compromised immune systems. The increasing prevalence of pneumonia is a key driver for the demand for effective therapeutics to address the condition.
Continued research and development endeavors have resulted in the identification of new treatment options and innovative approaches for pneumonia. These advancements have the potential to enhance the efficacy of existing treatments or introduce novel therapies, contributing to the expansion of the market and offering improved treatment outcomes for patients.
Restraints in the Global Pneumonia Therapeutics Market
Antibiotic resistance poses a significant challenge in the treatment of pneumonia. The overuse and misuse of antibiotics have led to the emergence of drug-resistant bacterial strains, diminishing the effectiveness of certain treatments. This constrains the available options for pneumonia treatment and underscores the necessity for alternative therapies.
The development and production of new pneumonia therapeutics often involve substantial costs, which can be transferred to patients and healthcare systems. The elevated expenses associated with treatment may restrict access to effective therapies, particularly in regions with limited healthcare resources or a lack of insurance coverage.
Market Trends of the Global Pneumonia Therapeutics Market
There was a growing emphasis on research and development in the field of pneumonia therapeutics. In response to the emergence of drug-resistant bacterial strains and the imperative for more effective treatments, pharmaceutical companies were actively investing in the development of novel antibiotics and alternative therapeutic approaches to combat pneumonia. This trend gained significance due to concerns about the potential for antibiotic-resistant infections.
Pneumonia, being a preventable disease, witnessed a strong focus on vaccination efforts, particularly for high-risk populations such as the elderly, young children, and individuals with compromised immune systems. Vaccines like the pneumococcal conjugate vaccine (PCV) and the influenza vaccine were actively promoted to reduce the incidence of pneumonia and its associated complications.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Pneumonia Therapeutics Market by Treatment
- Market Overview
- Antibiotics
- antiviral drugs
- and supportive care
Global Pneumonia Therapeutics Market by Distribution channel
- Market Overview
- Hospital pharmacies
- retail pharmacies
- and online platforms
Global Pneumonia Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (GSK) - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi - France
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. - Israel
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V. - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (now part of AbbVie) - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals - USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc. - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daiichi Sankyo Co., Ltd. - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
